PD-L1 (Programmed death ligand 1)

These findings suggest that HLA class I downregulation may contribute to ICI resistance.

Applying this framework, we consolidated hundreds of heterogeneous eligibility traits into a manageable set of clinical concepts and found that roughly half are both clinically important and plausibly inferable from routine structured and unstructured EHR data, while the remainder either add little value to prediction or depend on specialized testing. This taxonomy provides a prioritized "predictable target" list for future NLP and machine-learning models and a practical blueprint for designing more computable, pragmatic eligibility criteria and EHR-driven prescreening tools.

Immunotherapy has transformed oral squamous cell carcinoma management, with programmed cell death protein-1 inhibitors like nivolumab and pembrolizumab showing survival benefits in trials, particularly in programmed cell death protein-L1-positive cases. Future priorities include biomarker validation via prospective registries, scalable Good Manufacturing Practice nanoplatforms, AI-driven multi-omic modeling, and federated learning for predictive analytics. By integrating tumour genomics, immune profiling, and advanced delivery, precision immuno-oncology holds promise to improve response rates, durability, and quality of life in oral squamous cell carcinoma.

However, metabolic heterogeneity, compensatory pathway activation, limited biomarkers, and insufficient clinical validation remain major challenges. A glycolysis-centered understanding of ovarian cancer may support biomarker-guided combination strategies and improve translational therapeutic design.

AABS represents a paradigm shift from reactive to decision-based cancer immunotherapy, grounded in established immunological principles including T-cell multi-signal activation and kinetic proofreading. A five-phase experimental roadmap with quantitative endpoints is provided to guide preclinical and translational validation.

The incidence of grade 3-4 adverse events (AEs) was similar in three groups. Among the first-line treatment regimens for metastatic lung adenocarcinoma patients with negative or low PD-L1 expression, PD-1/PD-L1 inhibitors plus anti-angiogenic agents with chemotherapy showed significant benefit in PFS compared to anti-angiogenic agents plus chemotherapy and PD-1/PD-L1 inhibitors plus chemotherapy.

Therefore, we elucidate the mechanisms of immune resistance in EGFR-mutant patients and analyze the core immune mechanisms underlying EGFR-TKI resistance. We summarize the application of immune checkpoint inhibitors (ICIs) in advanced EGFR-mutant NSCLC and analyze the associated mechanisms of action.

In contrast, the same regimen showed inferior OS relative to many comparators (HR range for comparators vs. toripalimab plus chemotherapy: 0.47-0.65) and had the lowest OS ranking in SQ-NSCLC (SUCRA = 0.09). In the PD-L1 < 1% subgroup, nivolumab plus ipilimumab demonstrated a trend toward better OS compared with pembrolizumab plus chemotherapy (HR = 0.59) and ranked as the best regimen for SQ-NSCLC (SUCRA = 0.83), whereas pembrolizumab plus chemotherapy provided the greatest OS benefit for non-SQ-NSCLC (SUCRA = 0.90). In the PD-L1 ≥ 50% subgroup, atezolizumab plus chemotherapy ranked second for OS benefit in SQ-NSCLC but was the least effective combination in non-SQ-NSCLC; conversely, cemiplimab plus chemotherapy was the least effective combination in SQ-NSCLC but ranked second in non-SQ-NSCLC. The efficacy of individual first-line ICI regimens appear to vary by histological subtype across PD-L1 expression levels. These findings suggest that PD-L1 status alone might not be sufficient to guide treatment selection, and that histological subtype could be considered in clinical decision-making for advanced NSCLC.

SCore provides biologically interpretable transcriptomic framework for CRC risk stratification. The NOX4-centered data provide functional support for one component of this state, whereas the broader immune and circadian implications remain hypothesis-generating.

IHC confirmed PTK6 overexpression as an independent poor prognostic factor for OS (HR = 5.050, 95% CI 2.136-11.943, p < 0.001), associating with aggressive clinicopathological features (all p < 0.05). PTK6 represents a context-dependent prognostic biomarker linked to tumor immune microenvironment remodeling in UCEC, suggesting its potential utility for immunotherapeutic optimization.

In this real-world cohort, continuing ICI beyond progression was associated with significantly superior survival outcomes compared to switching to non-ICI regimens, with a manageable safety profile. CIBP represents a valid and promising second-line strategy for selected patients with advanced GC/GEJC following first-line immuno-chemotherapy failure.

Anlotinib demonstrated promising responses with manageable toxicity in a heavily pretreated R/M HNSCC population. Integration of genomic and immune microenvironment features may provide hypothesis-generating insights into patient selection.